CUE Cue Biopharma, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 14, 2026
$25,57
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$0,1752 haftanın en düşüğü
$45,5052 haftanın en yükseği
Piyasa Değeri (MRQ)
$134M
P/E (TTM)
-1.0
Hisse Başına Kâr (TTM)
$-25.24
Gelir (TTM)
$38M
rozetleriniz
52 Haftlık Aralık
$0–$46
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$88
P/E
-1.0
ROE
-1603.5%
Net Kâr Marjı
-435.8%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
CUE Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$25.57
Piyasa Değeri (MRQ)
$134M
P/E (TTM)
-1.0
Hisse Başına Kâr (TTM)
$-25.24
Gelir (TTM)
$38M
ROE (TTM)
-1603.5%
52 Haftlık Aralık
$0–$46
CUE Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 24 Nisan 2026 | 1-for-30 | Ters |
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$27M2018-12-31 → 2025-12-31
Hisse Başına Kâr$-0.282021-12-31 → 2025-12-31
Serbest Nakit Akışı$-22M2020-12-31 → 2025-12-31
Net kar marjı-435.8%2020-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | CUE | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -1.05Y ort. ≈-3.0 | ≈-3.0 | · | · | |
| F/S (TTM) | 3.65Y ort. ≈30.4 | ≈30.4 | 4.6 | Adil değer | |
| F/D (MRQ) | 57.95Y ort. ≈3.1 | ≈3.1 | 2.8 | Aşırı değerli | |
| Fiyat / Serbest Nakit Akışı (TTM) | -2.75Y ort. ≈-3.6 | ≈-3.6 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -2.75Y ort. ≈-3.7 | ≈-3.7 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 3.15Y ort. ≈3.1 | ≈3.1 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | CUE | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | -262.0%5Y ort. ≈-1212.1% | ≈-1212.1% | -226.0% | Zayıf | |
| EBITDA Margin (FAVÖK Marjı) | -96.7%5Y ort. ≈-1212.1% | ≈-1212.1% | -226.0% | Zayıf | |
| Net Kâr Marjı (TTM) | -435.8%5Y ort. ≈-1202.3% | ≈-1202.3% | -220.0% | Zayıf | |
| ROA (TTM) | -459.6%5Y ort. ≈-66.7% | ≈-66.7% | -30.4% | Zayıf | |
| ROE (TTM) | -1603.5%5Y ort. ≈-119.2% | ≈-119.2% | -58.5% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | CUE | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 1.35Y ort. ≈3.9 | ≈3.9 | 7.9 | Düşük likidite | |
| Quick Ratio (Cari Oran) | 2.45Y ort. ≈3.4 | ≈3.4 | 7.5 | Düşük likidite | |
| Interest Coverage (Faiz Karşılama Oranı) | -265.55Y ort. ≈-360.6 | ≈-360.6 | -20.1 | Düşük likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | CUE | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 195.8%5Y ort. ≈177.6% | ≈177.6% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 180.5%5Y ort. ≈62.0% | ≈62.0% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 54.2% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | CUE | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.75Y ort. ≈0.2 | ≈0.2 | 0.1 | En üst düzey | |
| Receivables Turnover (Alacak Devir Hızı) | 8.55Y ort. ≈5.8 | ≈5.8 | 6.0 | En üst düzey | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$947.1K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-248.9%
Sonraki Rapor
Kas 10, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 14, 2026 | $-24.14 | $-1.71 | -1314.3% |
| 30 Eylül 2025 | $-2.10 | $-2.83 | 25.7% | |
| 30 Haziran 2025 | $-2.70 | $-4.24 | 36.4% | |
| 31 Mart 2025 | $-5.10 | $-4.65 | -9.8% | |
| 31 Aralık 2024 | $-3.90 | $-4.73 | 17.5% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27M | $9M | $5M | $1M | $15M | $3M | $3M | $1M | |
| R&D Expense | $38M | $36M | $41M | $39M | $41M | $34M | $27M | $29M | |
| SG&A Expense | $16M | $15M | $17M | $16M | $17M | $15M | $13M | $11M | |
| Operating Expenses | $54M | $51M | $58M | $54M | $59M | $48M | $40M | $40M | |
| Operating Income | $-27M | $-42M | $-52M | $-53M | $-44M | $-45M | $-37M | $-39M | |
| Interest Expense | $100.0K | $100.0K | $100.0K | $109.0K | · | · | · | · | |
| Other Non-op | $450.0K | $826.0K | $1M | $215.0K | $45.9K | $463.9K | $482.8K | $165.3K | |
| Pretax Income | · | · | · | $-53M | $-44M | $-45M | $-36M | $-38M | |
| Income Tax | $500.0K | $0 | · | $0 | $495.0K | $206.2K | $412.5K | $825.0K | |
| Net Income | $-27M | $-41M | $-51M | $-53M | $-44M | $-45M | $-37M | $-39M | |
| EPS (Basic) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | · | · | · | |
| EPS (Diluted) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | · | · | · | |
| Shares (Basic) | 94,731,768 | 56,328,348 | 45,754,794 | 35,649,134 | 31,285,418 | · | · | · | |
| Shares (Diluted) | 94,731,768 | 56,328,348 | 45,754,794 | 35,649,134 | 31,285,418 | · | · | · | |
| EBITDA | $-27M | $-42M | $-52M | $-53M | $-44M | $-45M | · | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27M | $22M | $49M | $52M | $64M | $75M | $44M | $21M | |
| Receivables | $6M | $945.0K | $2M | $57.0K | $3M | $1M | $754.9K | · | |
| Prepaid Expense | $1M | $805.0K | $955.0K | $841.0K | $954.8K | $1M | $860.1K | $1M | |
| Current Assets | $37M | $25M | $51M | $77M | $68M | $88M | $61M | $41M | |
| PP&E (Net) | $241.0K | $471.0K | $795.0K | $1M | $2M | $2M | $2M | $3M | |
| PP&E (Gross) | $4M | $4M | $4M | $6M | $6M | $5M | $4M | $4M | |
| Accum. Depreciation | $4M | $4M | $4M | $4M | $3M | $3M | $2M | $1M | |
| Other Non-current Assets | $94.0K | $105.0K | $117.0K | $128.0K | $140.0K | $401.7K | $673.6K | $808.7K | |
| Total Assets | $42M | $32M | $62M | $91M | $83M | $100M | $72M | $45M | |
| Accounts Payable | $4M | $3M | $4M | $3M | $3M | $2M | $882.7K | $2M | |
| Accrued Liabilities | $2M | $3M | $4M | $4M | $5M | $3M | $2M | $2M | |
| Short-term Debt | · | $37.0K | $37.0K | $74.0K | · | · | · | · | |
| Current Liabilities | $13M | $14M | $17M | $12M | $13M | $16M | $12M | $6M | |
| Capital Leases | $2M | $1M | $3M | $6M | $5M | $2M | $1M | · | |
| Total Liabilities | $16M | $15M | $24M | $26M | $18M | $21M | $17M | $11M | |
| Long-term Debt | · | · | $4M | $8M | · | · | · | · | |
| Total Debt | · | $37.0K | $8M | $10M | · | · | · | · | |
| Common Stock | $3.0K | $62.0K | $47.0K | $43.0K | $32.2K | $30.4K | $26.6K | $20.7K | |
| Retained Earnings | $-368M | $-342M | $-301M | $-250M | $-197M | $-153M | $-109M | $-72M | |
| AOCI | · | $0 | $0 | $-96.0K | $0 | $7.1K | $-10.3K | $-11.0K | |
| Stockholders' Equity | $26M | $17M | $37M | $66M | $65M | $79M | $55M | $34M | |
| Liabilities + Equity | $42M | $32M | $62M | $91M | $83M | $100M | $72M | $45M | |
| Shares Outstanding | 3,220,707 | 61,819,101 | 47,215,116 | 47,215,116 | 32,202,496 | 30,351,366 | 26,562,178 | 20,697,453 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| D&A | $958.0K | $397.0K | $556.0K | $922.0K | $1M | $1M | $810.8K | $760.0K | |
| Stock-based Comp | $5M | $7M | $8M | $9M | $12M | $10M | $7M | $7M | |
| Amort. of Intangibles | · | · | · | · | · | $11.7K | $11.7K | · | |
| Operating Cash Flow | $-22M | $-36M | $-40M | $-42M | $-39M | $-32M | $-31M | $-26M | |
| CapEx | $177.0K | $66.0K | $0 | $171.0K | $913.0K | $595.3K | $46.4K | $2M | |
| Investing Cash Flow | $75.0K | $32.0K | $25M | $-25M | $9M | $4M | $3M | $-20M | |
| Stock Issued | $28M | $11M | $0 | $23M | $0 | $57M | $49M | · | |
| Stock Repurchased | · | · | $0 | $200.0K | $750.1K | $271.1K | $91.0K | · | |
| Net Stock Activity | $28M | $11M | $0 | $23M | $17M | $56M | · | · | |
| Financing Cash Flow | $26M | $10M | $12M | $54M | $19M | $59M | $51M | $4M | |
| Net Change in Cash | $5M | $-26M | $-3M | $-13M | $-10M | $31M | $23M | $-43M | |
| Taxes Paid | $500.0K | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-22M | $-36M | $-40M | $-42M | $-40M | $-33M | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -96.7% | -446.9% | -949.9% | -4274.3% | -292.6% | -1428.0% | · | · | |
| Net Margin | -96.9% | -438.0% | -924.1% | -4257.1% | -295.6% | -1419.8% | · | · | |
| Pretax Margin | · | · | · | -4257.1% | -292.2% | -1413.3% | · | · | |
| EBITDA Margin | -96.7% | -446.9% | -949.9% | -4274.3% | -292.6% | -1428.0% | · | · | |
| ROA | -71.5% | -86.8% | -66.4% | -60.7% | -48.3% | -52.3% | · | · | |
| ROE | -119.3% | -189.8% | -127.2% | -91.0% | -68.5% | -53.8% | · | · | |
| ROIC | · | · | · | -70.2% | -67.5% | -57.3% | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.7 | 1.8 | 3.0 | 6.7 | 5.4 | 5.4 | · | · | |
| Quick Ratio | 2.4 | 1.7 | 2.9 | 4.5 | 5.3 | 4.7 | · | · | |
| Debt / Equity | · | 0.0 | 0.2 | 0.2 | · | · | · | · | |
| LT Debt / Equity | · | 0.0 | 0.1 | 0.1 | · | · | · | · | |
| Interest Coverage | -265.5 | -415.0 | -401.1 | · | · | · | · | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.2 | 0.1 | 0.0 | 0.2 | 0.0 | · | · | |
| Receivables Turnover | 8.5 | 7.0 | 6.3 | 0.8 | 6.6 | 2.9 | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.27 | $0.28 | $0.86 | $1.53 | $2.03 | $2.60 | · | · | |
| Revenue / Share | $0.29 | $0.16 | $0.12 | $0.03 | · | · | · | · | |
| Cash Flow / Share | $-0.23 | $-0.65 | $-0.87 | $-1.17 | · | · | · | · | |
| Cash / Share | $0.28 | $0.36 | $1.13 | $1.20 | $2.00 | $2.47 | · | · | |
| EPS (TTM) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 195.8% | 69.2% | 341.0% | -91.7% | 373.7% | · | · | · | |
| Revenue CAGR 3Y | 180.5% | -14.7% | 20.3% | · | · | · | · | · | |
| Revenue CAGR 5Y | 54.2% | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $27M | $9M | $5M | $1M | $15M | $3M | $3M | $1M | |
| Net Income TTM | $-27M | $-41M | $-51M | $-53M | $-44M | $-45M | $-37M | $-39M | |
| Market Cap | $29M | $67M | $114M | $123M | $364M | $380M | · | · | |
| Enterprise Value | · | $45M | $73M | $81M | · | · | · | · | |
| P/E | -1.1 | -1.5 | -2.4 | -1.9 | -8.0 | · | · | · | |
| P/S | 1.1 | 7.3 | 20.7 | 98.5 | 24.4 | 120.4 | · | · | |
| P/B | 1.1 | 3.9 | 3.1 | 1.9 | 5.6 | 4.8 | · | · | |
| P / Tangible Book | 1.1 | 3.9 | 3.1 | 1.9 | 5.6 | 4.8 | · | · | |
| P / Cash Flow | -1.4 | -1.9 | -2.8 | -2.9 | -9.4 | -11.7 | · | · | |
| P / FCF | -1.3 | -1.9 | -2.8 | -2.9 | -9.2 | -11.5 | · | · | |
| EV / EBITDA | · | -1.1 | -1.4 | -1.5 | · | · | · | · | |
| EV / FCF | · | -1.2 | -1.8 | -1.9 | · | · | · | · | |
| EV / Revenue | · | 4.8 | 13.4 | 65.2 | · | · | · | · | |
| Earnings Yield | -91.8% | -66.1% | -42.0% | -52.3% | -12.5% | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $6M | $22M | $2M | $3M | $421.0K | $2M | $3M | $3M | $2M | $2M | $2M | $1M | $187.0K | $151.0K | $68.0K | |
| R&D Expense | $49M | $7M | $17M | $5M | $8M | $9M | $7M | $9M | $10M | $10M | $11M | $10M | $11M | $9M | $11M | $8M | |
| SG&A Expense | $47M | $4M | $3M | $5M | $4M | $4M | $4M | $3M | $4M | $4M | $5M | $4M | $4M | $4M | $4M | $4M | |
| Operating Expenses | $96M | $11M | $20M | $10M | $12M | $13M | $11M | $12M | $13M | $14M | $16M | $14M | $15M | $14M | $15M | $11M | |
| Operating Income | $-88M | $-5M | $2M | $-8M | $-9M | $-12M | $-10M | $-9M | $-10M | $-13M | $-14M | $-11M | $-14M | $-13M | $-15M | $-11M | |
| Interest Expense | · | · | · | · | $33.0K | $100.0K | · | · | · | $33.0K | $-537.0K | $254.0K | $350.0K | $33.0K | $18.0K | $33.0K | |
| Other Non-op | $-65M | $175.0K | $108.0K | $147.0K | $153.0K | $42.0K | $138.0K | $155.0K | $212.0K | $321.0K | $399.0K | $414.0K | $332.0K | $271.0K | $274.0K | $76.0K | |
| Net Income | $-153M | $-5M | $2M | $-7M | $-8M | $-12M | $-9M | $-9M | $-10M | $-12M | $-13M | $-11M | $-13M | $-13M | $-15M | $-11M | |
| EPS (Basic) | $-24.14 | $-1.08 | $0.05 | $-0.07 | $-2.67 | $-4.95 | $-0.10 | $-0.17 | $-0.20 | $-0.25 | $-0.29 | $-0.24 | $-0.29 | $-0.29 | $-0.37 | $-0.31 | |
| EPS (Diluted) | $-24.14 | $-1.08 | $0.05 | $-0.07 | $-2.67 | $-4.95 | $-0.10 | $-0.17 | $-0.20 | $-0.25 | $-0.29 | $-0.24 | $-0.29 | $-0.29 | $-0.37 | $-0.31 | |
| Shares (Basic) | 6,340,844 | 4,807,494 | · | 100,869,349 | 3,181,980 | 2,475,156 | · | 51,229,701 | 50,174,756 | 49,466,711 | · | 46,358,555 | 44,798,760 | 44,652,353 | · | 35,383,430 | |
| Shares (Diluted) | 6,340,844 | 4,807,494 | · | 100,869,349 | 3,181,980 | 2,475,156 | · | 51,229,701 | 50,174,756 | 49,466,711 | · | 46,358,555 | 44,798,760 | 44,652,353 | · | 35,383,430 | |
| EBITDA | $-88M | $-5M | · | $-8M | $-9M | $-12M | · | $-9M | $-10M | $-13M | · | $-11M | $-14M | $-13M | · | $-11M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17M | $16M | $27M | $12M | $27M | $13M | $22M | $32M | $30M | $41M | $49M | $55M | $53M | $56M | $52M | $30M | |
| Receivables | $5M | $5M | $6M | $387.0K | $532.0K | $0 | $945.0K | $3M | $2M | $1M | $2M | $2M | $1M | $196.0K | $57.0K | $796.0K | |
| Prepaid Expense | $2M | $2M | $1M | $3M | $2M | $2M | $805.0K | $2M | $2M | $2M | $955.0K | $1M | $2M | $2M | $841.0K | $2M | |
| Current Assets | $27M | $26M | $37M | $26M | $31M | $16M | $25M | $37M | $34M | $45M | $51M | $58M | $61M | $69M | $77M | $62M | |
| PP&E (Net) | $255.0K | $288.0K | $241.0K | $307.0K | $454.0K | $523.0K | $471.0K | $570.0K | $667.0K | $754.0K | $795.0K | $1M | $1M | $1M | $1M | $2M | |
| PP&E (Gross) | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $6M | $6M | $6M | $6M | $6M | |
| Accum. Depreciation | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $5M | $4M | $4M | $4M | |
| Other Non-current Assets | $88.0K | $90.0K | $94.0K | $96.0K | $283.0K | $102.0K | $105.0K | $108.0K | $111.0K | $114.0K | $117.0K | $120.0K | $123.0K | $125.0K | $128.0K | $131.0K | |
| Total Assets | $31M | $31M | $42M | $32M | $41M | $22M | $32M | $45M | $42M | $54M | $62M | $69M | $73M | $82M | $91M | $76M | |
| Accounts Payable | $4M | $3M | $4M | $2M | $4M | $4M | $3M | $6M | $4M | $4M | $4M | $2M | $2M | $2M | $3M | $2M | |
| Accrued Liabilities | $15M | $1M | $2M | $2M | $2M | $4M | $3M | $3M | $5M | $5M | $4M | $5M | $4M | $3M | $4M | $4M | |
| Short-term Debt | · | · | · | · | · | $100.0K | · | · | · | $37.0K | · | · | · | · | · | $37.0K | |
| Current Liabilities | $21M | $7M | $13M | $16M | $19M | $15M | $14M | $17M | $16M | $18M | $17M | $17M | $16M | $14M | $12M | $10M | |
| Capital Leases | $1M | $2M | $2M | $3M | $3M | $176.0K | $1M | $1M | $2M | $3M | $3M | $4M | $5M | $5M | $6M | $6M | |
| Total Liabilities | $28M | $9M | $16M | $18M | $23M | $16M | $15M | $19M | $21M | $24M | $24M | $26M | $27M | $27M | $26M | $26M | |
| Long-term Debt | · | · | · | · | · | · | · | $1M | $2M | $3M | · | $5M | $6M | $7M | · | $9M | |
| Total Debt | · | · | · | · | · | $100.0K | · | $5M | $6M | $7M | · | $9M | $10M | $10M | · | $10M | |
| Common Stock | $5.0K | $3.0K | $97.0K | $78.0K | $76.0K | $62.0K | $62.0K | $60.0K | $48.0K | $48.0K | $47.0K | $45.0K | $44.0K | $43.0K | $43.0K | $35.0K | |
| Retained Earnings | $-527M | $-374M | $-368M | $-370M | $-363M | $-354M | $-342M | $-332M | $-324M | $-314M | $-301M | $-288M | $-277M | $-264M | $-250M | $-236M | |
| AOCI | · | · | · | $1.0K | · | · | · | · | · | · | · | $0 | $-5.0K | $-39.0K | $-96.0K | $-92.0K | |
| Stockholders' Equity | $2M | $22M | $26M | $13M | $18M | $7M | $17M | $25M | $22M | $30M | $37M | $43M | $46M | $55M | $66M | $51M | |
| Liabilities + Equity | $31M | $31M | $42M | $32M | $41M | $22M | $32M | $45M | $42M | $54M | $62M | $69M | $73M | $82M | $91M | $76M | |
| Shares Outstanding | 5,229,392 | 3,255,359 | 96,621,218 | 77,781,743 | 76,446,884 | 61,819,101 | 61,819,101 | 60,207,717 | 48,643,316 | 48,643,316 | 47,215,116 | 45,123,281 | 43,744,414 | 43,178,150 | 47,215,116 | 35,385,582 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $36.0K | $566.0K | $678.0K | $80.0K | $99.0K | $101.0K | $98.0K | $101.0K | $99.0K | $99.0K | $113.0K | $130.0K | $136.0K | $177.0K | $203.0K | $201.0K | |
| Stock-based Comp | $24M | $48.0K | $610.0K | $2M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $-29M | $-11M | $-1M | $-9M | $-3M | $-8M | $-9M | $-8M | $-10M | $-10M | $-11M | $-8M | $-10M | $-11M | $-11M | $-7M | |
| CapEx | $0 | $121.0K | $0 | $0 | $27.0K | $150.0K | $2.0K | $-1.0K | $10.0K | $55.0K | $0 | $0 | $0 | $0 | $1.0K | $78.0K | |
| Investing Cash Flow | $0 | $-121.0K | $7M | $-7M | $-27.0K | $-150.0K | $-1.0K | $98.0K | $-10.0K | $-55.0K | $0 | $5M | $5M | $15M | $5M | $-30M | |
| Stock Issued | · | · | $10M | $0 | · | · | $-8.0K | $11M | · | · | · | · | · | · | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $9.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Financing Cash Flow | $30M | $306.0K | $9M | $1.0K | $18M | $-1M | $-932.0K | $10M | $-1M | $2M | $5M | $5M | $2M | $388.0K | $27M | $-9.0K | |
| Net Change in Cash | $1M | $-11M | $15M | $-16M | $14M | $-9M | $-10M | $2M | $-11M | $-7M | $-6M | $2M | $-3M | $5M | $22M | $-36M | |
| Free Cash Flow | · | $-11M | · | · | · | $-8M | · | · | · | $-10M | · | · | · | $-11M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1113.3% | -94.1% | · | -353.4% | -292.3% | -2921.4% | · | -264.2% | -390.6% | -737.8% | · | -543.8% | -978.1% | -7155.1% | · | -16222.1% | |
| Net Margin | -1943.2% | -91.1% | · | -346.6% | -287.1% | -2911.4% | · | -259.6% | -382.7% | -719.1% | · | -524.0% | -954.0% | -7010.2% | · | -16110.3% | |
| EBITDA Margin | -1113.3% | -94.1% | · | -353.4% | -292.3% | -2921.4% | · | -264.2% | -390.6% | -737.8% | · | -543.8% | -978.1% | -7155.1% | · | -16222.1% | |
| ROA | -428.7% | -19.5% | · | -19.5% | -20.4% | -32.2% | · | -15.2% | -17.6% | -18.2% | · | -15.2% | -16.7% | -15.2% | · | -14.1% | |
| ROE | -1495.6% | -36.7% | · | -38.6% | -42.6% | -67.0% | · | -25.5% | -30.1% | -29.0% | · | -23.6% | -24.9% | -21.9% | · | -19.2% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 3.6 | · | 1.7 | 1.6 | 1.0 | · | 2.2 | 2.1 | 2.5 | · | 3.3 | 3.7 | 5.0 | · | 6.0 | |
| Quick Ratio | 1.1 | 2.9 | · | 0.8 | 1.5 | 0.8 | · | 2.1 | 1.9 | 2.3 | · | 3.3 | 3.3 | 4.1 | · | 3.0 | |
| Debt / Equity | · | · | · | · | · | 0.0 | · | 0.2 | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -383.9 | · | -45.0 | -38.6 | -40.5 | · | -89.0 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.1 | 0.1 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 2.7 | 2.1 | · | 1.2 | 2.5 | 0.6 | · | 1.4 | 1.8 | 2.2 | · | 1.7 | 1.5 | 0.3 | · | 0.1 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.44 | $6.64 | · | $0.17 | $0.24 | $0.11 | · | $0.42 | $0.44 | $0.62 | · | $0.95 | $1.05 | $1.27 | · | $1.43 | |
| Revenue / Share | $1.24 | $1.18 | · | $0.02 | $0.03 | $0.01 | · | $0.07 | $0.05 | $0.03 | · | $0.05 | $0.03 | $0.00 | · | $0.00 | |
| Cash Flow / Share | · | $-2.28 | · | · | · | $-0.11 | · | · | · | $-0.20 | · | · | · | $-0.24 | · | · | |
| Cash / Share | $3.33 | $5.03 | · | $0.15 | $0.36 | $0.21 | · | $0.54 | $0.62 | $0.84 | · | $1.21 | $1.21 | $1.30 | · | $0.84 | |
| EPS (TTM) | $-25.24 | $-3.77 | · | $-7.79 | $-7.89 | $-5.42 | · | $-0.91 | $-0.98 | $-1.07 | · | $-1.19 | $-1.26 | $-1.34 | · | $-1.37 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $38M | $33M | · | $7M | $8M | $8M | · | $10M | $8M | $7M | · | $4M | $2M | $432.0K | · | $9M | |
| Net Income TTM | $-164M | $-20M | · | $-38M | $-39M | $-41M | · | $-45M | $-47M | $-50M | · | $-52M | $-52M | $-52M | · | $-47M | |
| Market Cap | $165M | $748.7K | · | $56M | $52M | $56M | · | $46M | $60M | $92M | · | $104M | $160M | $154M | · | $79M | |
| Enterprise Value | · | · | · | · | · | $43M | · | $18M | $37M | $58M | · | $58M | $117M | $108M | · | $59M | |
| P/E | -1.3 | -0.1 | · | -0.1 | -0.1 | -0.2 | · | -0.8 | -1.3 | -1.8 | · | -1.9 | -2.9 | -2.7 | · | -1.6 | |
| P/S | 4.4 | 0.0 | · | 7.9 | 6.3 | 7.0 | · | 4.8 | 7.3 | 13.1 | · | 27.2 | 89.3 | 356.8 | · | 8.4 | |
| P/B | 71.4 | 0.0 | · | 4.2 | 2.9 | 8.6 | · | 1.8 | 2.8 | 3.1 | · | 2.4 | 3.5 | 2.8 | · | 1.6 | |
| P / Tangible Book | 71.4 | 0.0 | · | 4.2 | 2.9 | 8.6 | · | 1.8 | 2.8 | 3.1 | · | 2.4 | 3.5 | 2.8 | · | 1.6 | |
| P / Cash Flow | · | -0.1 | · | · | · | -6.9 | · | · | · | -9.4 | · | · | · | -14.2 | · | · | |
| EV / Revenue | · | · | · | · | · | 5.4 | · | 1.9 | 4.4 | 8.3 | · | 15.2 | 65.4 | 249.8 | · | 6.3 | |
| Earnings Yield | -80.0% | -1639.1% | · | -1083.5% | -1156.9% | -594.9% | · | -120.2% | -79.0% | -56.6% | · | -51.7% | -34.5% | -37.5% | · | -61.4% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $27M | $9M | $5M | $1M | $15M |
| Faaliyet Kâr Marjı % | -96.7% | -446.9% | -949.9% | -4274.3% | -292.6% |
| Net Gelir | $-27M | $-41M | $-51M | $-53M | $-44M |
| Seyreltilmiş Hisse Başı Kâr | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | · | 0.0 | 0.2 | 0.2 | · |
| Cari Oran | 2.7 | 1.8 | 3.0 | 6.7 | 5.4 |
| Cari Oran | 2.4 | 1.7 | 2.9 | 4.5 | 5.3 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-22M | $-36M | $-40M | $-42M | $-40M |
Kurumsal Sahipler (13F) 3 dosya · $921K toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
3
Tutulan Değer
$921K
Yeni pozisyonlar
0
Çıkan pozisyonlar
54
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 0 | 54 | 0 | 0 | · |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır. Önceki çeyreğe göre değişim gösterilmiyor: başvuru sahibi kapsamı, güvenilir bir karşılaştırma için bu iki çeyrek arasında çok fazla farklılık göstermektedir.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| VANGUARD GROUP INC | $919.280 | 3.014.034 | 99,80% | Hisse senetleri |
| New Millennium Group LLC | $1.756 | 5.750 | 0,19% | Hisse senetleri |
| IFP Advisors, Inc | $55 | 100 | 0,01% | Hisse senetleri |
Aktivistler ve %5+ sahipler 2 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Shao-Lee Lin | 21 Ağustos 2026 | 6,20% | İlk başvuru | · | SEC |
| Christopher A. Marlett 2) ×2 başvurular | 21 Nisan 2020 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 35 içeriden öğrenenler · 18 yöneticiler · 19 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Shao-Lee Lin | Chief Executive Officer | 12 Ağustos 2026 M | 705.995 | 1 | 5 | $-606.596 |
| Usman Azam | CHIEF EXECUTIVE OFFICER | 29 Eylül 2025 A | · | 0 | 0 | $0 |
| Daniel R Passeri | CHIEF EXECUTIVE OFFICER | 21 Mart 2025 A | 164.578 | 0 | 0 | $0 |
| James M Ahlers | Chief Financial Officer | 30 Temmuz 2026 A | 25.500 | 0 | 0 | $0 |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER | 21 Mart 2025 A | 14.311 | 0 | 0 | $0 |
| Anish Suri | PRESIDENT AND CSO | 05 Haziran 2024 A | 135.638 | 0 | 0 | $0 |
| Michael Vincent Meluzio | VP, Prin. Accounting Officer | 13 Ağustos 2026 M | 48.961 | 0 | 3 | $-169.323 |
| Sumita Ray | Chief Legal Compliance Officer | 13 Ağustos 2026 M | 118.545 | 0 | 3 | $-265.629 |
| Dominique Christian Borie | Chief Medical Officer | 13 Temmuz 2026 A | 31.500 | 0 | 0 | $0 |
| Daniel G. Baker | CHIEF DEVELOPMENT OFFICER | 09 Nisan 2026 A | · | 0 | 0 | $0 |
| Lucinda Warren | CHIEF BUSINESS OFFICER | 09 Nisan 2026 A | · | 0 | 0 | $0 |
| Colin Sandercock | SVP, GENERAL COUNSEL | 09 Nisan 2026 A | 17.125 | 0 | 0 | $0 |
| Matteo Levisetti | Chief Medical Officer | 21 Mart 2025 A | · | 0 | 0 | $0 |
| Patricia Nasshorn | Chief Business Officer | 16 Şubat 2023 A | · | 0 | 0 | $0 |
| Kenneth Pienta | Chief Medical Officer | 25 Mart 2022 A | 2.000 | 0 | 0 | $0 |
| Bethany Mancilla | SVP and Chief Business Officer | 06 Mart 2019 A | · | 0 | 0 | $0 |
| Ronald D. Seidel III | EVP, Head of R&D | 23 Temmuz 2018 A | · | 0 | 0 | $0 |
| Rodolfo Chaparro | EVP, Head of Immunology | 23 Temmuz 2018 A | · | 0 | 0 | $0 |
| Viola Mong Meehan | Yönetim kurulu üyesi | 09 Temmuz 2026 A | 21.800 | 0 | 0 | $0 |
| Pasha Sarraf | Yönetim kurulu üyesi | 09 Temmuz 2026 A | 29.195 | 5 | 0 | $99.719 |
| Pamela Garzone | Yönetim kurulu üyesi | 09 Temmuz 2026 A | 18.900 | 0 | 0 | $0 |
| Daniel A. Camardo | Yönetim kurulu üyesi | 09 Temmuz 2026 A | 21.800 | 0 | 0 | $0 |
| Patrick Verheyen | Yönetim kurulu üyesi | 02 Ocak 2026 A | · | 0 | 0 | $0 |
| Frank Morich | Yönetim kurulu üyesi | 02 Ocak 2026 A | 28.000 | 0 | 0 | $0 |
| Peter A Kiener | Yönetim kurulu üyesi | 02 Ocak 2026 A | 357 | 0 | 0 | $0 |
| Jill Marie Broadfoot | Yönetim kurulu üyesi | 02 Ocak 2026 A | · | 0 | 0 | $0 |
| Frederick W Driscoll | Yönetim kurulu üyesi | 02 Ocak 2025 A | · | 0 | 0 | $0 |
| Michael J Fox | Yönetim kurulu üyesi | 05 Haziran 2024 A | · | 0 | 0 | $0 |
| Fletcher Aaron G.L. | Yönetim kurulu üyesi | 03 Ocak 2023 A | 940.000 | 0 | 0 | $0 |
| Tamar D Howson | Yönetim kurulu üyesi | 03 Ocak 2023 A | · | 0 | 0 | $0 |
| Cameron Gray | Yönetim kurulu üyesi | 14 Haziran 2022 X | 687.049 | 0 | 0 | $0 |
| Steven L Mcknight | Yönetim kurulu üyesi | 02 Ocak 2020 A | · | 0 | 0 | $0 |
| Christopher A Marlett | Yönetim kurulu üyesi | 02 Ocak 2020 A | 0 | 0 | 0 | $0 |
| Anthony DiGiandomenico | Yönetim kurulu üyesi | 24 Aralık 2018 P | 30.000 | 0 | 0 | $0 |
| Barry J. Simon | · | 04 Ocak 2021 A | · | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 3 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
CUE Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 6 analist
AL
Medyan hedef
$83.00
+224,6%
2 33,3%
Güçlü Al
3 50,0%
Al
1 16,7%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
3 analist · 2026-10-01Ortalama hedef $88.00 +244,2%
← Tüm hedeflerin altında
Mevcut fiyat $25.57
Düşük$66.00
Ortalama$88.00
Yüksek$115.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| CUE | $29M | -1.1 | 195.8% | -96.9% | -119.3% | · |
| ALEC | $172M | -1.1 | -79.1% | -679.2% | -280.7% | · |
| WHWK | $114M | -7.3 | -72.5% | -288.3% | -13.4% | · |
| TRDA | $394M | -3.0 | -87.9% | -565.5% | -41.9% | · |
| ELDN | $114M | -2.9 | · | · | -69.4% | · |
| PYXS | $72M | -0.9 | -14.2% | -574.5% | -112.9% | · |
| CHRS | $172M | 1.0 | 59.8% | 398.4% | 185.8% | · |
| NKTX | $131M | -1.3 | · | · | -31.1% | · |
| CNTN | $112M | -2.7 | · | · | -18.0% | · |
| ORGO | $658M | 34.5 | 17.0% | 6.6% | 13.9% | · |
| DTIL | $100M | -1.2 | -50.1% | -133.4% | -72.4% | · |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 14, 2026